Inflammatory Manifestations Associated With Gut Dysbiosis in Alzheimers Disease
Kozhakhmetov S. Kaiyrlykyzy A. Jarmukhanov Z. Vinogradova E. Zholdasbekova G. Alzhanova D. Kunz J. Kushugulova A. Askarova S.
2024Hindawi Limited
International Journal of Alzheimers Disease
2024#2024
Recent studies strongly suggest that gut microbiome can influence brain functions and contribute to the development of Alzheimers disease (AD). However, reported changes in the gut microbiomes in AD patients from different countries are not similar, and more research is needed to reveal the relationships between human microbiomes and AD in diverse ethnic populations. There is also an assumption that microbiome-associated peripheral inflammation might drive the development of sporadic AD. This cross-sectional study is aimed at analyzing the gut microbial profile and exploring potential associations with blood cytokines and some clinical parameters among individuals diagnosed with Alzheimers in Kazakhstan. Consistent with previous studies, we have found that the microbial landscape in AD reveals specific alterations in the gut microbiome. Specifically, the AD patient group showed a decreased Firmicutes/Bacteroidetes ratio. The differential abundance analysis highlighted a dysbiosis in the gut microbiota of AD patients, marked by a reduced presence of Bifidobacterium, particularly B. breve. In our study, AD patients altered gut microbiota composition notably features an increased presence of Pseudomonadota like Phyllobacterium and inflammatory bacteria such as Synergistetes and the Christensenellaceae family. The metabolic profiling of the AD microbiome reveals a predominant presence of pathways related to sugar, carrier molecules, tetrapyrrole, pyrimidine biosynthesis, and nucleic acid processing. This analysis also highlighted a marked reduction in SCFA, carbohydrate, polysaccharide, polyamine, and myo-inositol degradation pathways. The increases in the proinflammatory cytokines IL-1a, IL-8, IL-17A, IL-12p40, TNF-β, MCP-1, IL-2, and IL-12p70 and the anti-inflammatory cytokines IL-10 and IL-13 were observed in AD patients. Key variables driving the separation of AD and controls include inflammatory markers (IL-1a and IL-8), growth factors (EGF), lipids (LDL), BMI, and gut microbes, like genus Tyzzerella and Turicibacter and species Parabacteroides distasonis and Bacteroides eggerthii. We have also demonstrated that almost all cytokines strongly correlate with serum adiponectin levels and specific microbial taxa in AD patients. Thus, our findings identify potential microbial and inflammatory signatures in an ethnically distinct cohort of AD patients. These could serve as AD biomarkers and microbiota-based therapeutic targets for treating AD.
Text of the article Перейти на текст статьи
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
Faculty of Medicine and Healthcare, al-Farabi Kazakh National University, Almaty, Kazakhstan
Institute of Life Sciences, Medical University Karaganda, Karagandy, Kazakhstan
Department of Neurology, Medical University Astana, Astana, Kazakhstan
School of Medicine, Nazarbayev University, Astana, Kazakhstan
Center for Life Sciences
Faculty of Medicine and Healthcare
Institute of Life Sciences
Department of Neurology
School of Medicine
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026